drugset / Trial / NCT03568175
A Study of JR-141 in Patients With Mucopolysaccharidosis II
NaSingle-groupOpen-labelTreatment
Summary
A Phase II/ III multicenter, open-label, single-group, designed to evaluate the efficacy and safety of study drug for the treatment of the MPS II.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2020-02-20
- Completion
- 2020-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PABINAFUSP ALFA | Protein / enzyme biologic | 2 mg/kg | Intravenous |